Anzeige
Mehr »
Donnerstag, 11.09.2025 - Börsentäglich über 12.000 News
Diese Aktie sichert sich Exklusiv-Partnerschaft mit Babcock für Ukraine-Defence - Neubewertung voraus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12DEH | ISIN: CH0256379097 | Ticker-Symbol: 6ML
Frankfurt
11.09.25 | 08:09
2,870 Euro
-5,12 % -0,155
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULAR PARTNERS AG Chart 1 Jahr
5-Tage-Chart
MOLECULAR PARTNERS AG 5-Tage-Chart
RealtimeGeldBriefZeit
2,9153,18020:55

Aktuelle News zur MOLECULAR PARTNERS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.08.Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025625MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected...
► Artikel lesen
25.08.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3
21.08.Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics335Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21...
► Artikel lesen
25.06.MOLECULAR PARTNERS AG - S-8, Securities to be offered to employees in employee benefit plans15
22.06.Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025663MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor...
► Artikel lesen
11.06.Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025800Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, including...
► Artikel lesen
10.06.Molecular Partners kündigt Personalabbau zur Ausweitung der Liquiditätsreserven an8
MOLECULAR PARTNERS Aktie jetzt für 0€ handeln
10.06.Molecular Partners to cut jobs, cash reach now anticipated to extend into 20285
10.06.Molecular Partners baut einen Viertel der Belegschaft ab576Schlieren - Das Biotech-Unternehmen Molecular Partners tritt auf die Kostenbremse und baut bis zu 40 Arbeitsplätze ab. Ziel sei es, die Effizienz zu steigern, den Fokus stärker auf die Weiterentwicklung...
► Artikel lesen
10.06.Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway574Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
19.05.Molecular Partners to Present at Upcoming Investor Conferences567ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
16.05.Molecular Partners reports Q1 results2
15.05.Molecular Partners Reports Financial Results and Highlights from Q1 2025700Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical...
► Artikel lesen
15.05.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3
02.05.XFRA NEW INSTRUMENTS AVAILABLE ON 02.05.20257.551The following instruments on XETRA do have their first trading 02.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.05.2025 Aktien 1 CH0432492467 Alcon AG 2U3 2 CH0110240600...
► Artikel lesen
29.04.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer8
25.04.Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025728Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel...
► Artikel lesen
16.04.Molecular Partners Announces all Board Proposals Approved at Annual General Meeting648ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
25.03.Molecular Partners to hold three poster presentations at AACR 20251.533Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First...
► Artikel lesen
25.03.Molecular Partners Publishes Invitation to Annual General Meeting 2025630ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3